95 search results
- Current search:
- Haematological Malignancies
- Reset
Primary tabs
- Cochrane Evidence (active tab)
- Resources
- Handbooks & Manuals
- Training & Workshops
- News
- All Cochrane sites
-
TitlePublished 25 Jun 2017
Additional local therapies to increase efficacy of immune-checkpoint inhibition mediated immunotherapy for patients with cancer
Haematological Malignancies Group Sebastian Theurich Title Monday, June 19, 2017 ... -
Cochrane EvidencePublished 25 May 2017
Comparison of the two international standards of chemotherapy for people with early unfavourable or advanced stage Hodgkin lymphoma
Review question For the treatment of early unfavourable and advanced stage Hodgkin lymphoma (HL) two different international standards are commonly used, either chemotherapy with escalated (intensified) BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) regimen or chemotherapy with ABVD (doxorubicin, ... -
Cochrane EvidencePublished 27 Apr 2017
Treatment of early stage Hodgkin lymphoma
Background Hodgkin lymphoma (HL) is a malignancy of the lymphatic system. It occurs in children and adults, but it is more common in the third decade of life. It is one of the most curable forms of cancer. There are four stages of HL, stages I and II are considered as early stage HL and stages III and IV as advanced stage. Using risk factors such ... -
Cochrane EvidencePublished 26 Apr 2017
Interim PET for prognosis in adults with Hodgkin lymphoma: a prognostic factor exemplar review
Protocol: Primary objective The objective of this systematic review is to identify all studies evaluating interim PET scan results as a prognostic factor, describe the characteristics and risk of bias of included studies and if possible, meta-analyse results on the association between PET scan results and overall or progression-free survival ... -
Cochrane EvidencePublished 16 Apr 2017
Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta-analysis
Protocol: The objectives are to systematically review the effect of intravenous iron or no iron in combination with erythropoiesis-stimulating agents (ESAs) on the prevention or alleviation of anaemic cancer patients and to generate a clinically meaningful treatment ranking according to their safety and efficacy. -
TitlePublished 9 Apr 2017
Chimeric antigen receptor (CAR) T cell therapy for patients with relapsed B-cell malignancies
Haematological Malignancies Group Nicole Skoetz Title Saturday, April 1, 2017 ... -
Cochrane EvidencePublished 18 Mar 2017
Anti-herpesvirus prophylaxis versus placebo, no treatment or pre-emptive treatment in hemato-oncological malignancies
Protocol: We will assess the effects of anti-herpes drugs in hemato-oncological patients comparing prophylaxis versus placebo, no treatment or pre-emptive treatment. -
Cochrane EvidencePublished 17 Feb 2017
Nivolumab for adult individuals with Hodgkin lymphoma (an exemplar rapid review using RobotReviewer)
Protocol: To assess the benefits and harms of nivolumab in adult individuals with Hodgkin lymphoma (HL). -
Cochrane EvidencePublished 3 Feb 2017
Computerised decision support systems to promote appropriate use of blood products
Protocol: To assess the effect of computerised decision support systems (DSSs) on transfusion practice. -
TitlePublished 29 Jan 2017
Obinutuzumab for individuals with relapsed follicular lymphoma
Haematological Malignancies Group Nicole Skoetz Title Wednesday, January 11, 2017 ...